Navigation Links
Ambry Genetics Research Highlights Need for Expanded Genetic Testing Payer Coverage for Patients At-Risk for Hereditary Breast and Ovarian Cancer
Date:5/2/2019

Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, will present results documenting discrepancies between U.S. insurer policies for genetic testing and the 2019 National Comprehensive Cancer Network (NCCN) medical management guidelines for patients at risk for hereditary breast and ovarian cancer (HBOC).

Jill S. Dolinsky, director of clinical affairs at Ambry Genetics, explained why this research is significant: “Multigene panel testing (MGPT) is now the preferred method for clinicians testing for HBOC because it enables adherence to the latest NCCN guidelines, which now include medical management recommendations for people with mutations in 16 different genes. Unfortunately, adoption of MGPT has outpaced insurance coverage. We felt there was a need to quantify how current insurance coverage guidelines impact patient access to testing and subsequent clinical management.”

Ambry assessed MGPT orders for patients insured by three major insurance carriers. Results revealed significant disparities among insurers as to the number and type of the 16 genes outlined in NCCN management guidelines covered. On a patient level, overlaying these results with NCCN management guidelines indicate that 25.6% of patients who should consider breast MRI screening and 10.5% of patients who should consider risk-reducing surgery for ovarian cancer would be missed if testing was limited to the genes covered under the insurance medical policies.

“On the patient level, the impact of these discrepancies is serious,” said Rob Guigley, vice president of market access at Ambry Genetics. “In line with a limited number of the nation’s largest insurers, the data highlight the urgent need for payers to update their medical policy to be in step with the NCCN guidelines to ensure at-risk patients have access to HBOC genetic testing and can benefit from early detection and a potential reduction of their cancer risk."

Presentation #581999 is being presented on Friday, May 3rd, 2019, 6:00-7:30 PM at the ASBrS Annual Meeting.

About Ambry Genetics
Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer comprehensive and high-quality genetic testing. As part of the Konica Minolta family, Ambry Genetics is responsibly applying new technologies to the molecular diagnostics market to bring about precision medicine. With over 20 years of experience, Ambry Genetics has longstanding expertise in clinical genetic testing. For more information about Ambry Genetics, visit http://www.ambrygen.com.

Press Contact:
June Fujimoto
press(at)ambrygen.com
949-301-2454

Read the full story at https://www.prweb.com/releases/ambry_genetics_research_highlights_need_for_expanded_genetic_testing_payer_coverage_for_patients_at_risk_for_hereditary_breast_and_ovarian_cancer/prweb16280632.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Ambry Genetics Launches New Neurodevelopmental Genetic Testing Panel
2. Ambry Genetics to Present Seven Abstracts at Upcoming ACMG Annual Clinical Genetics Meeting
3. Ambry Genetics Shares New Data on Genetic Causes for Neurodevelopmental Conditions, Further Adding to Growing Body of Evidence in Neurology
4. JAMA Oncology Publishes Ambry’s Results Detailing Genes Associated with Hereditary Breast and Ovarian Cancer
5. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
6. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
7. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
8. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
9. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
10. Cytogenetics - Technologies, Markets and Companies - 2013
11. Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... September 01, 2020 , ... Slone Partners , ... announced the placement of Julianne Averill , CPA, as Chief Financial Officer ... operations and implementing key business strategies to accelerate Alveo’s growth as the company ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the ... its Scientific Advisory Board (SAB) to research the medical potential of terpenes and the ... when combined with terpenes. The board is focused on expanding the recently launched line ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), ... The network is a consortium of academic research centers in the United States ...
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine ... global leader in FDA compliance consulting has been named on its annual Inc. ... list represents a unique look at the most successful companies within the American ...
Breaking Biology Technology:
(Date:7/22/2020)... , ... July 21, 2020 , ... ... transformation and innovation in technology and compliance, announces a new solution to manage ... must ensure every layer of their technology stack complies with FDA and global ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced ... will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional ... Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global ... of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of ... located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical ...
Breaking Biology News(10 mins):